SynCon MERS DNA vaccine: Completed Phase I enrollment

GeneOne and Inovio completed enrollment of 75 healthy volunteers in an open-label, U.S. Phase I trial evaluating a 3-injection regimen of 0.67, 2 and 6 mg DNA per intramuscular dose of GLS-5300 follow...